815 related articles for article (PubMed ID: 30103794)
1. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.
Fujita A; Yamaguchi H; Yamasaki R; Cui Y; Matsuoka Y; Yamada KI; Kira JI
J Neuroinflammation; 2018 Aug; 15(1):227. PubMed ID: 30103794
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.
Martin HL; Santoro M; Mustafa S; Riedel G; Forrester JV; Teismann P
Glia; 2016 Mar; 64(3):386-95. PubMed ID: 26511587
[TBL] [Abstract][Full Text] [Related]
3. 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.
Ding H; Underwood R; Lavalley N; Yacoubian TA
Neuroscience; 2015 Oct; 307():73-82. PubMed ID: 26314634
[TBL] [Abstract][Full Text] [Related]
4. Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia.
Fang M; Yamasaki R; Li G; Masaki K; Yamaguchi H; Fujita A; Isobe N; Kira JI
Front Immunol; 2018; 9():2588. PubMed ID: 30464764
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective Effect of Echinacoside in Subacute Mouse Model of Parkinson's Disease.
Liang Y; Chen C; Xia B; Wu W; Tang J; Chen Q; Tang L; Yang H; Zhang Z; Lu Y; Yang Y; Zhao Y
Biomed Res Int; 2019; 2019():4379639. PubMed ID: 30834264
[TBL] [Abstract][Full Text] [Related]
6. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
[TBL] [Abstract][Full Text] [Related]
7. Aquaporin-4 mediates communication between astrocyte and microglia: Implications of neuroinflammation in experimental Parkinson's disease.
Sun H; Liang R; Yang B; Zhou Y; Liu M; Fang F; Ding J; Fan Y; Hu G
Neuroscience; 2016 Mar; 317():65-75. PubMed ID: 26774050
[TBL] [Abstract][Full Text] [Related]
8. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
[TBL] [Abstract][Full Text] [Related]
9. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
Watanabe Y; Kato H; Araki T
Metab Brain Dis; 2008 Mar; 23(1):51-69. PubMed ID: 18030609
[TBL] [Abstract][Full Text] [Related]
10. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.
Parillaud VR; Lornet G; Monnet Y; Privat AL; Haddad AT; Brochard V; Bekaert A; de Chanville CB; Hirsch EC; Combadière C; Hunot S; Lobsiger CS
J Neuroinflammation; 2017 Mar; 14(1):60. PubMed ID: 28320442
[TBL] [Abstract][Full Text] [Related]
11. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
12. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F
J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.
Rojo AI; Innamorato NG; Martín-Moreno AM; De Ceballos ML; Yamamoto M; Cuadrado A
Glia; 2010 Apr; 58(5):588-98. PubMed ID: 19908287
[TBL] [Abstract][Full Text] [Related]
14. Ghrelin-AMPK Signaling Mediates the Neuroprotective Effects of Calorie Restriction in Parkinson's Disease.
Bayliss JA; Lemus MB; Stark R; Santos VV; Thompson A; Rees DJ; Galic S; Elsworth JD; Kemp BE; Davies JS; Andrews ZB
J Neurosci; 2016 Mar; 36(10):3049-63. PubMed ID: 26961958
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
16. Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.
Luellen BA; Miller DB; Chisnell AC; Murphy DL; O'Callaghan JP; Andrews AM
J Pharmacol Exp Ther; 2003 Dec; 307(3):923-31. PubMed ID: 14561848
[TBL] [Abstract][Full Text] [Related]
17. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
18. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
19. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.
Qi X; Davis B; Chiang YH; Filichia E; Barnett A; Greig NH; Hoffer B; Luo Y
J Neurochem; 2016 Sep; 138(5):746-57. PubMed ID: 27317935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]